Who is the CEO of Crossject SA?

Mr. Patrick Alexandre is a business executive who currently serves as the CEO of Crossject SA.

What is the Revenue Growth of Crossject SA?

Revenue growth data for Crossject SA is currently unavailable.

What is Crossject SA operating Margin?

Crossject SA operating margin is -312.34% which shows how much profit ALCJ.PA earns from each dollar of sales, after subtracting the direct costs tied to generating that revenue.

In which market sector does Crossject SA operate?

Crossject SA falls under the Healthcare sector which thrives across multiple industries. It stays competitive through its diverse product lineup, which spans computer hardware, tech gadgets, video streaming services, and cloud computing solutions.

What is Crossject SA revenue growth?

Revenue growth data for Crossject SA is currently unavailable.

Crossject SA

ALCJ.PA•EURONEXT

HealthcareMedical - Instruments & Supplies

€1.85

€0.06(3.58%)

Crossject SA (ALCJ.PA) Stock Overview

Explore Crossject SA’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for ALCJ.PAStats details for ALCJ.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations data is not available for ALCJ.PAAnalyst Recommendations details for ALCJ.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.

CEO

Mr. Patrick Alexandre

Employees

112

Headquarters

6 Rue Pauline Kergomard, Dijon

Founded

2014